Immuneering To Present at Guggenheim 2023 Oncology Conference
January 31 2023 - 6:50AM
Immuneering Corporation (Nasdaq: IMRX), a clinical stage
biopharmaceutical company that aims to create medicines for all
patients with solid tumors driven by RAS mutations and other MAPK
pathway activating events, today announced that management will
present at Guggenheim’s 2023 Oncology Conference to discuss the
company’s pipeline, platform, and business strategy. Participating
will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer
of Immuneering.
Format: Fireside ChatDate: Feb 9, 2023Time: 3:20 - 3:45 PM
ET
The presentations will be webcast live and archived for 30 days
in the Investor Relations section of Immuneering’s website at
Events & Presentations | Immuneering Corporation.
About Immuneering CorporationImmuneering is a
clinical stage biopharmaceutical company that aims to create
medicines for all patients with solid tumors driven by RAS
mutations and other MAPK pathway activation events. Immuneering is
evaluating its lead product candidate, IMM-1-104, in a Phase 1/2a
study in patients with advanced solid tumors harboring RAS
mutations (NCT05585320). IMM-1-104 aims to achieve pan-RAS activity
that selectively impacts cancer cells to a greater extent than
healthy cells, through deep cyclic inhibition of the MAPK pathway
with once-daily dosing. Deep cyclic inhibition is a novel mechanism
that aims to deprive tumor cells of the sustained proliferative
signaling required for rapid growth, while providing a cadenced,
normalized level of signaling designed to spare healthy cells. This
new mechanism was engineered using Immuneering's proprietary
informatics-based discovery platform, and the development of
Immuneering's pipeline is translationally guided by the Company's
proprietary, human-aligned 3D tumor platform combined with
patient-aligned bioinformatics. Immuneering's second product
candidate, IMM-6-415, is designed to provide deep cyclic inhibition
of the MAPK pathway with an accelerated cadence relative to the
once daily dosing of IMM-1-104. IMM-6-415 is currently in
IND-enabling studies. Immuneering's earlier drug discovery pipeline
includes five additional targeted oncology programs as well as two
neuroscience programs.
Media Contact:Gina NugentNugent
Communications617-460-3579gina@nugentcommunications.com
Investor Contact:Laurence WattsGilmartin
Group619-916-7620laurence@gilmartinir.com
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jul 2023 to Jul 2024